Cargando…
Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro
Subvisible proteinaceous particles which are present in all therapeutic protein formulations are in the focus of intense discussions between health authorities, academics and biopharmaceutical companies in the context of concerns that such particles could promote unwanted immunogenicity via anti-dru...
Autores principales: | Rombach-Riegraf, Verena, Karle, Anette C., Wolf, Babette, Sordé, Laetitia, Koepke, Stephan, Gottlieb, Sascha, Krieg, Jennifer, Djidja, Marie-Claude, Baban, Aida, Spindeldreher, Sebastian, Koulov, Atanas V., Kiessling, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897673/ https://www.ncbi.nlm.nih.gov/pubmed/24466023 http://dx.doi.org/10.1371/journal.pone.0086322 |
Ejemplares similares
-
Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?
por: Sordé, Laetitia, et al.
Publicado: (2017) -
Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?
por: Sordé, Laetitia, et al.
Publicado: (2017) -
T cell epitope mapping of secukinumab and ixekizumab in healthy donors
por: Spindeldreher, Sebastian, et al.
Publicado: (2020) -
Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
por: Karle, Anette, et al.
Publicado: (2016) -
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
por: Spindeldreher, Sebastian, et al.
Publicado: (2018)